证券代码：300981 证券简称：中红医疗 公告编号：2023-063 中红普林医疗用品股份有限公司 2023 年第四次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东大会没有出现否决提案的情形。 2. 本次股东大会不涉及变更以往股东大会已通过决议的情形。 一、会议召开情况和出席情况 1. 会议召开时间： 现场会议召开时间：2023 年 8 月 28 日（星期一）14:30。 网络投票时间：2023 年 8 月 28 日。其中，通过深圳证券交易所交易系统进 行网络投票的时间为 2023 年 8 月 28 日 9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网系统投票的具体时间为 2023 年 8 月 28 日 9:15 至 15:00 的任意时间。 2. 现场会议召开地点：北京市经济技术开发区科创六街 87 号四楼会议室 3. 会议召开方式：现场会议和网络投票相结合的方式 4. 会议召集人：公司董事会 7. 股东出席的总体情况： 通过现场和网络投票的股东及股东代表 9 ...

北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2023 年第四次临时股东大会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2023 年第四次临时股东大会的法律意见 （二）《中红普林医疗用品股份有限公司股东大会议事规则》； 北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2023 年第四次临时股东大会的 法律意见 德恒 01G20230298-03 号 致：中红普林医疗用品股份有限公司 中红普林医疗用品股份有限公司（以下简称"公司"）2023 年第四次临时 股东大会（以下简称"本次会议"）于 2023 年 8 月 28 日（星期一）召开。北京 德恒律师事务所（以下简称"德恒"）受公司委托，指派吴莲花律师、赵亮亮律 师（以下简称"德恒律师"），根据《中华人民共和国证券法》（以下简称"《证 券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、中国证券监 督管理委员会《上市公司股东大会规则》（以下简称"《股东大会规则》"）、《中 红 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300981 证券简称：中红医疗 公告编号：2023-062 中红普林医疗用品股份有限公司 关于注销部分首次公开发行股票募集资金专项账户的公告 | 序号 | 户名 | 开户行名称 | 银行账号 | 账户状态 | | --- | --- | --- | --- | --- | | 1 | 中红普林医疗用品股 | 中国建设银行股份有 | 13050162743600002773 | 正常使用 | | | 份有限公司 | 限公司滦南支行 | | | | 2 | 中红普林医疗用品股 | 中国银行股份有限公 | 101740300607 | 正常使用 | | | 份有限公司 | 司滦南支行 | | | | 3 | 中红普林医疗用品股 | 中国光大银行股份有 | 79320188000322503 | 正常使用 | | | 份有限公司 | 限公司唐山分行 | | | | 4 | 中红普林医疗用品股 | 国家开发银行厦门市 | 35201560002039260000 | 本次注销 | | | 份有限公司 | 分行 ...

证券代码：300981 证券简称：中红医疗 公告编号：2023-058 一、会议召开情况 中红普林医疗用品股份有限公司（以下简称"公司"）第三届董事会第二十 一次会议于 2023 年 8 月 10 日以通讯方式召开，2023 年 8 月 7 日公司以电话和 电子邮件方式向全体董事发出会议通知（全体董事已同意豁免本次临时董事会通 知的时间要求）。会议应出席董事 9 人，实际出席董事 9 人，会议由董事长桑树 军先生主持，公司监事、高管和相关人员列席了会议。本次会议的召集、召开符 合相关法律、法规和公司章程的规定。 二、会议审议情况 1. 审议通过《关于召开 2023 年第四次临时股东大会的议案》 根据《公司法》《公司章程》等相关法律法规、规范性文件的规定，监事会 向董事会提议召开临时股东大会，审议《关于补选公司非职工代表监事的议案》。 与会董事同意该提议，并决定于 2023 年 8 月 28 日（星期一）召开 2023 年第四 次临时股东大会审议上述议案，股权登记日为 2023 年 8 月 21 日（星期一）。 表决结果为：同意 9 票，反对 0 票，弃权 0 票。 具体内容详见公司同日披露于巨潮资讯网（htt ...

证券代码：300981 证券简称：中红医疗 公告编号：2023-060 中红普林医疗用品股份有限公司 关于公司监事会主席辞职暨补选非职工代表监事的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会主席辞职情况 中红普林医疗用品股份有限公司（以下简称"公司"）监事会于近日收到公 司监事会主席许忠贤先生递交的书面辞职报告，许忠贤先生因到龄退休，申请辞 去公司第三届监事会主席、监事职务，许忠贤先生原定任期至第三届监事会期限 届满为止，辞去上述职务后不再担任公司任何职务。 根据《公司法》及《公司章程》的有关规定，许忠贤先生的辞职将导致公司 监事会成员低于法定最低人数，其辞职申请将自公司股东大会选举产生新任监事 后生效，在此期间许忠贤先生将继续履行监事会主席、监事相应职责，直至公司 股东大会补选产生新任监事。公司监事会将尽快按照法定程序完成监事补选及监 事会主席的选举工作。 周朝华先生简历及相关情况详见附件。 特此公告。 中红普林医疗用品股份有限公司 监事会 二〇二三年八月十日 许忠贤先生未持有公司股票，在担任公司监事会主席期间，秉持独立、客观、 专业的原 ...

中红普林医疗用品股份有限公司 第三届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 证券代码：300981 证券简称：中红医疗 公告编号：2023-059 表决结果为：同意 3 票，反对 0 票，弃权 0 票。 具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn）上 的《关于公司监事会主席辞职暨补选非职工代表监事的公告》（公告编号：2023- 060）。 2. 审议通过《关于向董事会提议召开临时股东大会的议案》 根据《公司法》《公司章程》等相关法律法规、规范性文件的规定，经公司 股东厦门国贸控股集团有限公司推荐，监事会同意提名周朝华先生为公司第三届 监事会非职工代表监事候选人，特向董事会提议召开临时股东大会审议《关于补 选非职工代表监事的议案》。 中红普林医疗用品股份有限公司（以下简称"公司"）第三届监事会第十五 次会议于 2023 年 8 月 10 日以通讯方式召开，2023 年 8 月 7 日公司以电话和电 子邮件方式向全体监事发出会议通知（全体监事已同意豁免本次临时监事会通 ...

证券代码：300981 证券简称：中红医疗 公告编号：2023-061 中红普林医疗用品股份有限公司 关于召开 2023 年第四次临时股东大会的通知 公司第三届董事会第二十一次会议于2023年8月10日召开，会议审议通过了 《关于召开2023年第四次临时股东大会的议案》。 3. 会议召开的合法、合规性：本次股东大会的召开符合有关《公司法》、 《证券法》、《公司章程》、《股东大会议事规则》和深交所业务规则等规定。 4. 会议召开的日期、时间： （1）现场会议时间：2023年8月28日14:30起。 （2）网络投票时间： 通过深圳证券交易所交易系统于交易时间进行网络投票的具体时间为 2023 年 8 月 28 日 9:15—9:25，9:30—11:30 和 13:00－15:00； 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）第三届董事会第二 十一次会议决定于 2023 年 8 月 28 日（星期一）召开 2023 年第四次临时股东大 会，会议有关事项通知如下： 一、召开会议的基本情况 1. 股东大会届次：20 ...

证券代码：300981 证券简称：中红医疗 中红普林医疗用品股份有限公司 2023 年 5 月 30 日投资者关系活动记录表 编号：2023—004 | --- | --- | --- | |--------------|--------------------------------------|--------------------------------| | | □ 特定对象调研 | 分析师会议 | | 投资者关系活 | □ 媒体采访 | 业绩说明会 | | 动类别 | □ 新闻发布会 | 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 | | | | 及人员姓名 | 参加河北辖区上市公司 | 年度网上集体接待日活动的投资者 | | 时间 | 2023 年 5 月 30 日 | 15:00--17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（ | https://ir.p5w.net）采 | | | 用网络远程的方式召开业绩说明会 | | | 上市公司接待 | 1、董事会秘书：张琳波先生 | | 人员姓名 2、证券事务代表：郭蕊女士 投资者提 ...

Financial Performance - The company reported a decline in both operating revenue and net profit due to a substantial drop in glove product prices, while major costs such as raw materials and energy did not decrease proportionately[4]. - The company's operating revenue for 2022 was ¥1,572,568,513.46, a decrease of 67.97% compared to ¥4,909,310,936.58 in 2021[22]. - The net profit attributable to shareholders for 2022 was ¥66,916,009.08, down 97.14% from ¥2,341,903,887.00 in 2021[22]. - The basic and diluted earnings per share for 2022 were both ¥0.22, a decline of 97.42% from ¥15.33 in 2021[22]. - The net cash flow from operating activities for 2022 was ¥106,707,621.94, a decrease of 95.48% compared to ¥2,362,497,600.00 in 2021[22]. - The total assets at the end of 2022 were ¥6,816,635,272.66, a decrease of 4.69% from ¥7,151,721,020.00 at the end of 2021[22]. - The net assets attributable to shareholders at the end of 2022 were ¥6,119,377,660.00, down 6.63% from ¥6,554,161,190.00 at the end of 2021[22]. - The company reported a total revenue of 1.5 billion RMB for the year 2022, representing a year-on-year increase of 15%[179]. - The gross profit margin improved to 40%, up from 35% in the previous year, reflecting better cost management and pricing strategies[178]. Market Dynamics - The company's main products, nitrile gloves, saw a significant increase in production and sales volume in Q4 compared to Q3, indicating a market recovery trend[4]. - The report highlights a clear indication of price stabilization for related products, strengthening market recovery expectations[4]. - The global demand for disposable health protective gloves is projected to grow to 12.851 billion units by 2025, with a compound annual growth rate (CAGR) of 15.9%[35]. - The market for nitrile gloves is expected to see a CAGR of approximately 19.8%, indicating strong future demand[35]. - The company has faced significant competition in the disposable glove market, leading to a decrease in product prices and profit margins, but signs of recovery are emerging[36]. Strategic Initiatives - The company aims to improve competitiveness through cost reduction, efficiency enhancement, and product line diversification[4]. - The company is closely monitoring domestic and international market dynamics and has adjusted its competitive strategy to enhance efficiency and product quality[4]. - The company has established new divisions including the Health Protection Division, Safety Infusion Division, and Innovation Incubation Division to expand its product offerings in high-margin medical device segments[34]. - The company plans to expand into innovative medical devices, medical services, biomedicine, and functional foods, focusing on anesthesia devices, minimally invasive surgical instruments, and rehabilitation equipment[41]. - The company aims to enhance its product line and revenue while mitigating market volatility risks through strategic acquisitions and product diversification[43]. Research and Development - The company has a total of 133 patents, including 34 invention patents, indicating a strong focus on innovation and R&D capabilities[68]. - The number of R&D personnel increased to 424 in 2022, a rise of 43.24% compared to 296 in 2021[88]. - R&D expenditure amounted to ¥42,718,557.03 in 2022, representing 2.72% of operating revenue, down from 3.62% in 2021[88]. - The company is focusing on improving the vulcanization speed of nitrile gloves without increasing energy consumption, which is expected to enhance product quality and release production capacity[86]. - The company is enhancing the tear resistance of PVC gloves by increasing the thickness at the wrist, which is expected to improve product quality and meet customer needs[86]. Governance and Management - The company has established a governance structure compliant with relevant laws and regulations, ensuring effective operation of its board and committees[156]. - The board consists of 9 members, including 3 independent directors, and has held 10 meetings during the reporting period, adhering to legal and regulatory requirements[159][160]. - The company maintains independent operations in terms of assets, personnel, finance, institutions, and business, ensuring no control or occupation by the controlling shareholder or actual controller[165]. - The company has a complete and independent business operation system, with no reliance on related transactions with shareholders or other related parties for its main business income and profits[169]. - The company actively engages with investors and research institutions, ensuring timely responses to inquiries and maintaining transparency[163]. Future Outlook - Future plans and projections are subject to uncertainties related to international political conditions, national policy changes, and market supply-demand relationships[5]. - The company anticipates a positive outlook for 2023, projecting continued revenue growth and market expansion[174]. - The company plans to optimize production processes and improve product quality to reduce customer complaints and returns[131]. - The company aims to enhance its market presence by introducing innovative medical devices that meet evolving healthcare needs[91]. - The company is focusing on expanding its market presence and enhancing product development to drive future growth[174].

Financial Performance - The company's operating revenue for Q1 2023 was ¥431,749,545.61, a decrease of 24.62% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥6,174,718.09, representing a decline of 110.04% year-on-year[5]. - The net cash flow from operating activities was -¥65,298,553.10, a significant decrease of 591.04% compared to the previous year[5]. - The company reported a basic earnings per share of -¥0.02, down 109.52% from ¥0.37 in the same period last year[5]. - The company reported a net loss of CNY 4,361,228.42, compared to a net profit of CNY 61,518,191.92 in the same period last year, representing a significant decline[33]. - Operating profit for the quarter was CNY -8,684,238.37, down from CNY 77,215,326.15 in Q1 2022, indicating a substantial decrease in operational performance[33]. - The company recorded a total comprehensive loss of CNY -3,866,854.86, contrasting with a comprehensive income of CNY 61,373,142.62 in Q1 2022[33]. - Total revenue for Q1 2023 was CNY 431,749,545.61, a decrease of 24.6% compared to CNY 572,751,113.34 in Q1 2022[31]. - Total revenue from sales of goods and services was CNY 421,809,319.01, a decrease of approximately 4.96% from CNY 443,825,751.85 in the previous year[35]. Assets and Liabilities - The total assets at the end of the reporting period were ¥7,566,889,327.28, an increase of 11.01% from the end of the previous year[5]. - The company's total liabilities increased significantly, with contract liabilities rising by 76.49% to ¥124,257,582.96, mainly due to mergers and acquisitions[10]. - Non-current liabilities rose to CNY 371,746,810.68, compared to CNY 39,879,106.82 in the previous year, indicating a substantial increase in long-term obligations[30]. - The total equity attributable to shareholders was CNY 6,113,697,316.01, slightly down from CNY 6,119,377,660.54 in the previous year, indicating stability in shareholder value despite revenue decline[30]. Cash Flow - The net cash flow from financing activities rose by 596.12% to ¥346,171,565.46, driven by increased borrowings[14]. - The company experienced a net cash outflow from investing activities of CNY -211,878,225.67, compared to a net inflow of CNY 356,097,663.62 in the same period last year[36]. - Cash and cash equivalents at the end of the period totaled CNY 597,618,503.71, down from CNY 1,247,903,989.89 at the end of Q1 2022[36]. - As of March 31, 2023, the company's cash and cash equivalents amounted to ¥639.28 million, an increase from ¥484.76 million at the beginning of the year[28]. Research and Development - Research and development expenses increased by 132.78% to ¥5,288,254.19, primarily due to mergers and acquisitions[12]. - Research and development expenses increased to CNY 5,288,254.19, up 132.3% from CNY 2,271,784.38 in Q1 2022, highlighting a focus on innovation[31]. - The company has successfully developed a new polyurethane condom technology that can physically inactivate 99.7% of HIV, addressing global issues related to polyurethane condom production[21]. - The company has implemented a dual-layer glove technology that enhances safety during high-risk surgeries, showcasing its commitment to innovation in medical supplies[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,783[16]. - The top shareholder, China Red Plum Group Co., Ltd., holds 45.00% of shares, totaling 135,000,000 shares[16]. - The total number of restricted shares held by major shareholders remains unchanged, with a release date set for April 27, 2024[19]. - The company reported a total of 205,507,500 restricted shares at the end of the period, with no shares released during the reporting period[19]. Strategic Initiatives - The company acquired 70% of Guilin Hengbao Health Protection Co., Ltd. for 541 million RMB to expand its product line in the medical device industry[18]. - Guilin Hengbao is a leading manufacturer of latex medical gloves and condoms, enhancing the company's market position[18]. - The company plans to maintain its focus on expanding its product offerings in the medical device sector[18]. - The company aims to strengthen its leading position in the glove industry through strategic acquisitions[18]. - The company has introduced several new product lines, including high-barrier condoms and various specialized gloves, aimed at expanding its market presence[20]. - The company initiated a share buyback program to stabilize its stock price after the share price fell below the net asset value per share for 20 consecutive trading days[22]. - The company was selected as a "Demonstration Enterprise for Creating World-Class Specialized and Innovative Enterprises," which is expected to enhance its brand value and industry influence[26]. Inventory and Costs - The company reported an increase in inventory to ¥545.28 million from ¥421.65 million at the beginning of the year, indicating a potential buildup of stock[28]. - Total operating costs for Q1 2023 were CNY 453,712,775.31, down from CNY 500,478,382.66 in the same period last year, reflecting a reduction of 9.3%[31]. - Gross profit margin for Q1 2023 was approximately 8.5%, compared to 20.2% in Q1 2022, indicating a significant decline in profitability[31].